Note Payable (Details) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2013 |
|
| Note Payable (Textual) | |||
| Amortization of debt discount | $ 196 | $ 196 | |
| Alzheimer's Drug Discovery Foundation [Member] | |||
| Note Payable (Textual) | |||
| Grant total | $ 205,260 | ||
| Debt instrument, description | The Notes have a term of four years the first installment on the notes matured on January 21, 2017 and was paid in March 2017. The second installment will become due on September 12, 2017. | ||
| Purchase warrant | 15,596 | ||
| Warrant exercise price per share | $ 0.99 | ||
| Warrant expiring term | The warrant expires on the 10 year anniversary of the grant date. | ||
| Deferred debt discount | $ 785 | ||
| Alzheimer's Drug Discovery Foundation [Member] | Minimum [Member] | |||
| Note Payable (Textual) | |||
| Promissory Notes interest rates | 3.25% | ||
| Alzheimer's Drug Discovery Foundation [Member] | Maximum [Member] | |||
| Note Payable (Textual) | |||
| Promissory Notes interest rates | 3.50% | ||
| X | ||||||||||
- Definition Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. No definition available.
|
| X | ||||||||||
- Definition Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees). No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Warrant expiring term. No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|